Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Revisiting farnesyltransferase inhibitors for head and neck cancer

Jared Weiss • 3 Jun 2020
ASCO 2020
Head and Neck Cancer Tipifarnib

Jared Weiss, MD, of UNC Lineberger, Chapel Hill, NC, discusses the use of tipifarnib, a farnesyltransferase inhibitor, in HRAS mutated head and neck cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Jared Weiss

2:22
Impact of antibiotic use on checkpoint inhibitor efficacy
Jared Weiss • 3 Jun 2020
3:05
ASCO 2020: head and neck cancer highlights
Jared Weiss • 3 Jun 2020
4:22
Myelopreservation and reduced use of supportive care with trilaciclib in patients with SCLC
Jared Weiss • 3 Jun 2020
4:24
Reflections on the ADAURA study
Jared Weiss • 3 Jun 2020

Related Videos

1:03
Challenges in implementing liquid biopsies for head and neck cancer
Mouadh Barbirou • 7 Apr 2024
2:43
Molecular profiling of tumor biomarkers in head and neck cancer
Mouadh Barbirou • 7 Apr 2024
1:40
The future of squamous cell carcinoma research at ESMO Asia 2023
Brian Henick • 6 Dec 2023
0:54
The role of immunotherapy in PD-L1 low advanced squamous cell carcinoma
Brian Henick • 6 Dec 2023
The content of VJOncology is intended for healthcare professionals